Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;20(3):583-9.
doi: 10.1007/s00520-011-1127-7. Epub 2011 Mar 5.

Falls in persons with chemotherapy-induced peripheral neuropathy

Cindy Tofthagen  1 , Janine Overcash, Kevin Kip
Affiliations

Falls in persons with chemotherapy-induced peripheral neuropathy

Cindy Tofthagen et al. Support Care Cancer. 2012 Mar.

Abstract

Purpose: The purpose of this study was to evaluate possible risk factors for falls in a group of patients with chemotherapy-induced peripheral neuropathy (CIPN).

Methods: This prospective, descriptive study included persons receiving paclitaxel, docetaxel, oxaliplatin, or cispatin who reported at least one symptom of CIPN. Each patient was invited to complete the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT) and a demographic data questionnaire. Data were analyzed using descriptive statistics and logistic regression.

Results: In this sample (n = 109), fallers (n = 21) had higher doses of chemotherapy(p = 0.045), more neuropathic symptoms (p = 0.016), higher scores on the symptom experience (p = 0.005) and interference items (=0.001) on the CIPNAT, more severe muscle weakness (p < 0.001) and loss of balance (p < 0.001), and higher interference with walking(p < 0.001) and driving (p = 0.022). Patients who received taxanes were more likely to have fallen than patients who received platinum-based chemotherapy (p = 0.022). No significant differences in age or disease stage between fallers and non-fallers were present. Severity of loss of balance and cycle number was independently associated with falling.

Conclusions: This study demonstrates that the risk of falls increases with each cycle of chemotherapy and that patients receiving taxanes may be at greater risk of falls than patients receiving neurotoxic platinum-based drugs. Patients who report muscle weakness and loss of balance or say that their symptoms interfere with walking or driving may be at a higher risk of falls.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Funded by an American Cancer Society Doctoral Scholarship in Cancer Nursing (DSCN-08-205-01). Authors have no financial relationship with the organization that sponsored the research and have full control of all primary data. We agree to allow the journal to review our data if requested.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. CDC. Injury Prevention & Control: Home and Recreational Safety. 2010 www.cdc.gov/homeandrecreationalsafety/falls/adults/adultfalls.htlm.
    1. Overcash J. Prediction of falls in older adults with cancer: a preliminary study. Oncol Nurs Forum. 2007;34(2):341–346. - PubMed
    1. Holley S. A look at the problem of falls among people with cancer. Clin J Oncol Nurs. 2002;6(4):193–197. - PubMed
    1. Joseph EK, Levine JD. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J Pain. 2009;10(5):534–541. - PMC - PubMed
    1. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. Journal of Clinical Oncology. 2006;24(10):1633–1642. - PubMed

Publication types

MeSH terms